The leading pharmaceutical company Mylan N.V signed an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited’s thrombosis business in Europe for approximately $754 million.
- The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
In May 2020, Mylan N.V announced, as part of its ongoing efforts to support patients and public health needs during the COVID-19 pandemic, a global collaboration with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19.
In April 2020, Mylan N.V. and Biocon Ltd. announced the launch of Fulphila, a biosimilar to Neulasta® (pegfilgrastim). Fulphila is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
In Nov 2019, Mylan N.V. and Pfizer Inc. announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘vi?-tr?s).
Mylan, headquartered in Canonsburg, Pennsylvania, United States, is a leading pharmaceutical company. The company offers a portfolio of more than 7,500 marketed products globally, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. The companys products are available in more than 165 countries and territories. The company has a workforce of approximately 35,000 people across the globe.